Contribution of TP53 and RB1 to lineage plasticity prostate cancer (Dr. Seynabou Diop, Postdoc)
We are investigating the contribution of RB1 and TP53 loss of function to the development and progression of AR-negative metastatic castration-resistant prostate cancer (ARN mCRPC including double-negative prostate cancer (DNPC) and neuroendocrine prostate cancer (NEPC)). We plan to identify genes which in combination with loss of function of TP53 or RB1 have clinical relevance such as resistance to AR-directed therapy and evidence of cell plasticity including neuroendocrine characteristics.
